Godwin Mary E.'s Form 4 filing
Nautilus Biotechnology, Inc. (NAUT) · filed Sep 25, 2024
- Accession no.
- 0001808805-24-000067
- Filed
- Sep 25, 2024, 6:29 PM ET
- Trade date
- Sep 23, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $134.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Godwin Mary E.CIK 0001439716 | Officer (Senior VP, Operations) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 23, 2024 | Common Stock | MOption exerciseAcquired | +47,031 | $0.46 | +$21,634.26 | 47,031 | Direct | |
| Sep 23, 2024 | Common Stock | SSaleDisposed | −47,031 | $2.87F1 | −$134,743.82 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 23, 2024 | Common Stock | MOption exerciseDisposed | −47,031 | $0.00 | $0 | 353,337 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the weighted average share price of an aggregate total of 47,031 shares purchased in the price range of $2.80 to $3.02 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.